Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004033 · ClinicalTrials.gov registry record · Phase 2
Liposomal-Cisplatin Analogue (L-NDDP) in Treating Patients With Malignant Pleural Mesothelioma
A Phase 2 study of Malignant Mesothelioma, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 2
- Study locations
NCT00004033: Completed Phase 2 study of Malignant Mesothelioma, sponsored by NYU Langone Health.
NCT00004033 is a Phase 2 study of Malignant Mesothelioma that has completed, run by NYU Langone Health. The registered enrollment target is 30 participants, below the 73-participant average among 11 other Malignant Mesothelioma trials with a reported enrollment target (59% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004033, a Phase 2 study of Malignant Mesothelioma, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 2
- Study locations
Study Summary
RATIONALE: Patient abstract not available PURPOSE: Patient abstract not available
Conditions Studied
Interventions
- DRUG liposomal NDDP
- PROCEDURE therapeutic thoracoscopy
Study Locations (2)
New York
- NYU School of Medicine's Kaplan Comprehensive Cancer Center - New York
Texas
- University of Texas - MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 1998-09 |
| Phase | Phase 2 |
What the finished NCT00004033 record still lists
NCT00004033 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 73-participant average among 11 other Malignant Mesothelioma trials with a reported enrollment target (59% lower).
The record links to 1 condition, with Malignant Mesothelioma appearing as the primary indexed condition, and to 2 interventions - of which liposomal NDDP is the first listed.
NCT00004033 reports a single indexed study location in New York, Texas.
Frequently Asked Questions
What is clinical trial NCT00004033 about?
NCT00004033 is a clinical study titled "Liposomal-Cisplatin Analogue (L-NDDP) in Treating Patients With Malignant Pleural Mesothelioma". RATIONALE: Patient abstract not available PURPOSE: Patient abstract not available
What is the current status of trial NCT00004033?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 1998-09.
What conditions does trial NCT00004033 study?
This clinical trial studies the following conditions: Malignant Mesothelioma.
What interventions are being tested in trial NCT00004033?
The interventions under investigation include: liposomal NDDP (DRUG), therapeutic thoracoscopy (PROCEDURE).
Who is sponsoring clinical trial NCT00004033?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00004033 being conducted?
This trial has 2 study locations across New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Mesothelioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00004033's enrollment target sits among peer trials
30 7th of 11 higher than 4 of 11 other Malignant Mesothelioma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Malignant Mesothelioma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma
RECRUITING · Phase 2
-
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
RECRUITING · Phase 2
-
Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer
COMPLETED · Phase 2
-
Gemcitabine and Epirubicin in Treating Patients With Malignant Mesothelioma
COMPLETED · Phase 2
-
Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer
COMPLETED · Phase 2
-
Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia